|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||152.69 - 155.17|
|52 Week Range||118.10 - 156.34|
|Beta (3Y Monthly)||0.65|
|PE Ratio (TTM)||25.20|
|Earnings Date||Jul 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||158.77|
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICON Public Limited Company (ICLR) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that it will present DIA Live – a social media aggregation site that allows visitors to track and analyse Twitter conversations from delegates at the DIA Global Annual Meeting (23 - 27 June, San Diego, CA).
ICON PLC NASDAQ/NGS:ICLRView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ICLR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ICLR. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $38 million over the last one-month into ETFs that hold ICLR are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as ICON Public Limited...
The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired a majority shareholding in MeDiNova Research, a site network with research sites in key markets in Europe and Africa, and that it has the right to acquire the remaining shares in the company by Quarter 3 2020. The acquisition further enhances ICON’s patient recruitment capabilities in EMEA and complements ICON’s existing site network in the US, PMG Research.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has been awarded the Clinical Research Team of the Year (with Eli Lilly and Company), for the second consecutive year, and Best in Health Economics and Outcomes Research (with Bristol-Myers Squibb and LATITUDE, powered by AXON). The awards indicated are ICON’s third win for Clinical Research Team of the Year since the inaugural CARE Awards in 2016, and first win in the Best Health Economics and Outcomes Research category. ICON and Eli Lilly and Company won the award for the successful execution of a full-service Cardiovascular Outcomes Trial (CVOT), in which they were able to achieve exceptional patient retention despite early challenges.
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced the release of its web based patient engagement platform, to provide patients with study specific information and connectivity with the nearest investigative site. The solution supplements patient recruitment outreach by sites and increases visibility of potential study participants for sponsors and sites. Patient recruitment specialists work with sponsors to develop outreach programs that incorporate the right mix of digital channels, traditional methods and patient advocacy partnerships to attract patients to a study branded website hosted on the platform.
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.88% and 0.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Dublin-based company said it had profit of $1.63 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings ...
Icon PLC (ICLR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
"Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on a lighter note, a good company can see its share price rise well over 100%. For instance, t...